AstraZeneca 082120

Blue avatar for guest contributors
By :  ,  Financial Analyst

AstraZeneca: drug approval in Japan

AstraZeneca’s Imfinzi has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer, in combination with etoposide plus a choice of platinum chemotherapy.

From a chartist point of view, the stock consolidates above a key support at 8310. As long as this level is not broken, a bounce would be expected towards 9113 at first.

Source : TradingVIEW, Gain Capital

Open an account today

Experience award-winning platforms with fast and secure execution.

Web Trader platform

Our sophisticated web-based platform is packed with features.
Economic Calendar